Table 2

Correlation analyses of PRO endpoints at month 3

HAQ-DISF-36v2† PFSF-36v2† BPPain-VASEQ-5D-3L P/D
Tofacitinib 5 mg twice daily (N=101)
 SF-36v2† PF10.64−0.56−0.38
 SF-36v2† BP1−0.70−0.50
 EQ-5D-3L P/D1
Tofacitinib 10 mg twice daily (N=103)
 SF-36v2† PF10.68−0.52−0.43
 SF-36v2† BP1−0.65−0.60
 EQ-5D-3L P/D1
Adalimumab 40 mg subcutaneous injection once every 2 weeks (N=100)
 SF-36v2† PF10.74−0.63−0.61
 SF-36v2† BP1−0.74−0.70
 EQ-5D-3L P/D1
Placebo (N=102)
 SF-36v2† PF10.72−0.57−0.44
 SF-36v2† BP1−0.58−0.39
 EQ-5D-3L P/D1
  • All correlations were **p<0.01, based on Student’s t distribution (N-2 degree of freedom) to test the null hypothesis of no correlation; the analysis included patients with observations at a visit of interest in the Full Analysis Set; N is the number of patients included in calculating the sample correlation.

  • †SF‑36v2 scores are norm-based.

  • BID, twice daily; BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions 3-level questionnaire; HAQ‑DI, Health Assessment Questionnaire Disability Index; P/D, pain/discomfort; PF, physical functioning; PRO, patient-reported outcome; SF-36v2, Short Form-36 Health Survey version 2; VAS, visual analogue scale.